Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
Takahiro Masuda, Shigeaki Muto, Keiko Fukuda, et al.
Physiological Reports (2020) Vol. 8, Iss. 2
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 49
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Adriana Marton, Tatsuroh Kaneko, Jean‐Paul Kovalik, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 1, pp. 65-77
Closed Access | Times Cited: 109
Glucose transporters in the kidney in health and disease
Volker Vallon
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1345-1370
Open Access | Times Cited: 102
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Rachel J. Perry, Gerald I. Shulman
Journal of Biological Chemistry (2020) Vol. 295, Iss. 42, pp. 14379-14390
Open Access | Times Cited: 83
A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
Yujie Xing, Biaohu Liu, Shujun Wan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 58
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 58
SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice
Rogério N. Soares, Francisco I. Ramirez‐Perez, Francisco J. Cabral-Amador, et al.
GeroScience (2022) Vol. 44, Iss. 3, pp. 1657-1675
Open Access | Times Cited: 41
Sodium–glucose cotransporter‐2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Jan Biegus, Marat Fudim, Husam M. Salah, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1526-1536
Open Access | Times Cited: 23
State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications
Volker Vallon
American Journal of Hypertension (2024) Vol. 37, Iss. 11, pp. 841-852
Closed Access | Times Cited: 13
The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
H. Salman, Adeeb A. Al-Zubaidy, Alaa Hamza Abbas, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 13
How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?
Volker Vallon
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 10, pp. 1565-1573
Closed Access | Times Cited: 12
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7833-7833
Open Access | Times Cited: 70
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara, Takahiro Masuda, Masato Morinari, et al.
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
Kana N. Miyata, Chao‐Sheng Lo, Shuiling Zhao, et al.
Clinical Science (2021) Vol. 135, Iss. 7, pp. 943-961
Open Access | Times Cited: 48
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities
Beatriz Martín-Carro, Javier Donate‐Correa, Sara Fernández-Villabrille, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10309-10309
Open Access | Times Cited: 21
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches
Georgiana Frățilă, Gabriela Elena Lupusoru, Bogdan Sorohan, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 569-569
Open Access | Times Cited: 8
Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat
Paulo C. Castro, Thiago M. Santos-Rios, Flavia L. Martins, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 6, pp. C1573-C1589
Closed Access | Times Cited: 6
Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
James Shaffner, Bohan Chen, Deepak Malhotra, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 35
Drug repurposing in autosomal dominant polycystic kidney disease
Julie Zhou, Vicente E. Torres
Kidney International (2023) Vol. 103, Iss. 5, pp. 859-871
Open Access | Times Cited: 14
The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
Yasunori Miyamoto, Akira Honda, Seiji Yokose, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2253-2253
Open Access | Times Cited: 14
Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease
Takahiro Masuda, Daisuke Nagata
Hypertension Research (2023) Vol. 46, Iss. 5, pp. 1195-1201
Closed Access | Times Cited: 13
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun‐Ho Kim, Sungjin Chung
Endocrinology and Metabolism (2023) Vol. 38, Iss. 4, pp. 359-372
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top